Literature DB >> 31385356

Covalent versus Noncovalent Binding of Ruthenium η6 -p-Cymene Complexes to Zinc-Finger Protein NCp7.

Yaping Sheng1, Zhuanghao Hou1, Shiyong Cui1, Kaiming Cao1, Siming Yuan1, Mei Sun2, Jakob Kljun3, Guangming Huang1, Iztok Turel3, Yangzhong Liu1.   

Abstract

Ruthenium-arene complexes are a unique class of organometallic compounds that have been shown to have prominent therapeutic potencies. Here, we have investigated the interactions of Ru-cymene complexes with a zinc-finger protein NCp7, aiming to understand the effects of various ligands on the reaction. Five different binding modes were observed on selected Ru-complexes. Ru-cymene complex can bind to proteins through either noncovalent binding alone or through a combination of covalent and noncovalent binding modes. Moreover, the noncovalent interaction can promote the coordination of RuII to NCp7, resulting synergistic effects of the different ligands. The binding of Ru(Cym) complexes leads to dysfunction of NCp7 through zinc-ejection and structural perturbation. These results indicate that the reactivity of Ru-complexes can be modulated by ligands through different approaches, which could be closely correlated to their different therapeutic effects.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  ligand effects; metallodrugs; noncovalent interactions; proteins; reaction mechanisms; ruthenium

Mesh:

Substances:

Year:  2019        PMID: 31385356     DOI: 10.1002/chem.201902434

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  6 in total

1.  The interactions of the ruthenium(II)-cymene complexes with lysozyme and cytochrome c.

Authors:  Dragana Stanic-Vucinic; Stefan Nikolic; Katarina Vlajic; Mirjana Radomirovic; Jelena Mihailovic; Tanja Cirkovic Velickovic; Sanja Grguric-Sipka
Journal:  J Biol Inorg Chem       Date:  2020-02-04       Impact factor: 3.358

2.  Ruthenium complexes show potent inhibition of AKR1C1, AKR1C2, and AKR1C3 enzymes and anti-proliferative action against chemoresistant ovarian cancer cell line.

Authors:  Jakob Kljun; Renata Pavlič; Eva Hafner; Tanja Lipec; Sara Moreno-Da Silva; Primož Tič; Iztok Turel; Tomaž Büdefeld; Jure Stojan; Tea Lanišnik Rižner
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

3.  Organoruthenium Complexes with Benzo-Fused Pyrithiones Overcome Platinum Resistance in Ovarian Cancer Cells.

Authors:  Jerneja Kladnik; James P C Coverdale; Jakob Kljun; Hilke Burmeister; Petra Lippman; Francesca G Ellis; Alan M Jones; Ingo Ott; Isolda Romero-Canelón; Iztok Turel
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

4.  Comparison of Solution Chemical Properties and Biological Activity of Ruthenium Complexes of Selected β-Diketone, 8-Hydroxyquinoline and Pyrithione Ligands.

Authors:  Tamás Pivarcsik; Gábor Tóth; Nikoletta Szemerédi; Anita Bogdanov; Gabriella Spengler; Jakob Kljun; Jerneja Kladnik; Iztok Turel; Éva A Enyedy
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-27

5.  Structural Isomerism and Enhanced Lipophilicity of Pyrithione Ligands of Organoruthenium(II) Complexes Increase Inhibition on AChE and BuChE.

Authors:  Jerneja Kladnik; Samuel Ristovski; Jakob Kljun; Andrea Defant; Ines Mancini; Kristina Sepčić; Iztok Turel
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

6.  Binding Kinetics of Ruthenium Pyrithione Chemotherapeutic Candidates to Human Serum Proteins Studied by HPLC-ICP-MS.

Authors:  Katarina Marković; Radmila Milačič; Stefan Marković; Jerneja Kladnik; Iztok Turel; Janez Ščančar
Journal:  Molecules       Date:  2020-03-26       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.